Clinical trials: Molecular Residual Disease, open to volunteers
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Pancreatic Cancer, Resectable Carcinoma
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer.
- Trial name
- MAP-02 (NCT05802407)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Neuroblastoma
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma.
- Trial name
- NCT07516678
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer (MSI-H), Molecular Residual Disease
Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite…
- Trial name
- NCT07775950
- Testing
- Discontinue NA Treatment, Continued Immunotherapy, Observation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, HER2-positive Breast Cancer
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
This is a Phase 2 study for patients with resected Stage I-III HER2+ breast cancer with detected molecular residual disease (MRD+) following standard neoadjuvant and locoregional therapy delivered with curative intent.
- Trial name
- NCT05388149
- Testing
- Neratinib
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Cancer, Lung Cancer
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular…
- Conditions
- Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer
- Trial name
- UMBRELLA (NCT06332274)
- Testing
- Tislelizumab, Blood sampling
- Where
- France
- Volunteers
- 717 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
HER2-positive Breast Cancer, Metastatic Cancer
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced…
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic
- Trial name
- PRE-ISPY (NCT05868226)
- Testing
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab
- Where
- 10 sites in United States
- Volunteers
- 280 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Small Cell Lung Carcinoma
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
This study plans to enroll limited-stage small cell lung cancer (LS-SCLC) patients who have achieved disease control after concurrent chemoradiotherapy (cCRT).
- Trial name
- NCT07357532
- Testing
- Adebrelimab Injection, Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Peking University Cancer Hospital & Institute
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
This phase II trial tests reduced post surgery (adjuvant) therapy for patients with early breast cancer who have confirmed that the disease has responded completely (pathologic complete response) after pre surgical treatment…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07407920
- Testing
- Biospecimen Collection, Hormone Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma
Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer
Gastric cancer is one of the most prevalent and lethal malignancies in China. The majority of patients are diagnosed at the locally advanced stage.
- Trial name
- NCT07034742
- Testing
- Intraperitoneal chemotherapy PLUS systemic chemotherapy
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Residual Disease
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional…
- Conditions
- Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
- Trial name
- PREDICT-RD (NCT07069595)
- Testing
- Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally…
- Trial name
- MERIDIAN (NCT05414032)
- Testing
- AZD2936
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease.
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT06529822
- Testing
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Washington University School of Medicine
Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the…
- Conditions
- Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
- Trial name
- NCT07551596
- Testing
- Balstilimab, Biopsy Procedure, Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Non-small Cell Lung Cancer
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed.
- Trial name
- NCT05965024
- Where
- China
- Volunteers
- 377 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer, Regorafenib
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
- Conditions
- Colorectal Cancer, Regorafenib, High Risk Patients
- Trial name
- NCT07071961
- Testing
- Regorafenib (CT), Lorigerlimab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lung Cancer
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD).
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Gynecologic Cancer
- Trial name
- SHERLOCK (NCT07524114)
- Where
- Canada
- Volunteers
- 7,000 people
- Sponsor
- University Health Network, Toronto